Chromocell Therapeutics Stock Buy Hold or Sell Recommendation
| CHRO Stock | USD 1.80 0.38 17.43% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Chromocell Therapeutics is 'Cautious Hold'. The recommendation algorithm takes into account all of Chromocell Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Chromocell Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Chromocell Stock, please use our How to Invest in Chromocell Therapeutics guide. In addition, we conduct extensive research on individual companies such as Chromocell and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Chromocell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Chromocell |
Execute Chromocell Therapeutics Buy or Sell Advice
The Chromocell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Chromocell Therapeutics. Macroaxis does not own or have any residual interests in Chromocell Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Chromocell Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
6 Months |
Risk Tolerance
I can tolerate above average risk |
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Chromocell Therapeutics Trading Alerts and Improvement Suggestions
| Chromocell Therapeutics is way too risky over 90 days horizon | |
| Chromocell Therapeutics may become a speculative penny stock | |
| Chromocell Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (7.38 M) with loss before overhead, payroll, taxes, and interest of (3.19 M). | |
| Chromocell Therapeutics generates negative cash flow from operations | |
| Chromocell Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 87.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: ZRG Expands CHRO Practice with Dan Kaplan and Beverly Morgan to Meet the Evolving Needs of HR Leaders |
Chromocell Therapeutics Returns Distribution Density
The distribution of Chromocell Therapeutics' historical returns is an attempt to chart the uncertainty of Chromocell Therapeutics' future price movements. The chart of the probability distribution of Chromocell Therapeutics daily returns describes the distribution of returns around its average expected value. We use Chromocell Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Chromocell Therapeutics returns is essential to provide solid investment advice for Chromocell Therapeutics.
| Mean Return | 2.89 |
| Value At Risk | -14.49 |
| Potential Upside | 25.28 |
| Standard Deviation | 15.81 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Chromocell Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Chromocell Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Chromocell Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Chromocell Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Chromocell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 3.18 | |
β | Beta against Dow Jones | 3.99 | |
σ | Overall volatility | 15.95 | |
Ir | Information ratio | 0.19 |
Chromocell Therapeutics Volatility Alert
Chromocell Therapeutics is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Chromocell Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Chromocell Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Chromocell Therapeutics Fundamentals Vs Peers
Comparing Chromocell Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Chromocell Therapeutics' direct or indirect competition across all of the common fundamentals between Chromocell Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Chromocell Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Chromocell Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Chromocell Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Chromocell Therapeutics to competition |
| Fundamentals | Chromocell Therapeutics | Peer Average |
| Return On Asset | -5.56 | -0.14 |
| Current Valuation | 14.17 M | 16.62 B |
| Shares Outstanding | 6.03 M | 571.82 M |
| Shares Owned By Insiders | 86.78 % | 10.09 % |
| Shares Owned By Institutions | 12.80 % | 39.21 % |
| Number Of Shares Shorted | 84.73 K | 4.71 M |
| Price To Book | 4.11 X | 9.51 X |
| Gross Profit | (3.19 M) | 27.38 B |
| EBITDA | (6.86 M) | 3.9 B |
| Net Income | (7.38 M) | 570.98 M |
| Total Debt | 1.27 M | 5.32 B |
| Book Value Per Share | (0.24) X | 1.93 K |
| Cash Flow From Operations | (981.03 K) | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | (1.81) X | 3.12 X |
| Target Price | 8.5 | |
| Number Of Employees | 4 | 18.84 K |
| Market Capitalization | 13.14 M | 19.03 B |
| Total Asset | 96.39 K | 29.47 B |
| Retained Earnings | (13.52 M) | 9.33 B |
| Working Capital | (6.44 M) | 1.48 B |
| Current Asset | 317 K | 9.34 B |
| Current Liabilities | 166 K | 7.9 B |
| Net Asset | 96.39 K |
Note: Acquisition by Friedberg Ezra M of 24533 shares of Chromocell Therapeutics at 0.64 subject to Rule 16b-3 [view details]
Chromocell Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Chromocell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1710.34 | |||
| Daily Balance Of Power | (1.19) | |||
| Rate Of Daily Change | 0.83 | |||
| Day Median Price | 1.96 | |||
| Day Typical Price | 1.91 | |||
| Price Action Indicator | (0.35) | |||
| Period Momentum Indicator | (0.38) |
About Chromocell Therapeutics Buy or Sell Advice
When is the right time to buy or sell Chromocell Therapeutics? Buying financial instruments such as Chromocell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Chromocell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 122 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Chromocell Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Chromocell Stock, please use our How to Invest in Chromocell Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromocell Therapeutics. If investors know Chromocell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromocell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chromocell Therapeutics is measured differently than its book value, which is the value of Chromocell that is recorded on the company's balance sheet. Investors also form their own opinion of Chromocell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chromocell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromocell Therapeutics' market value can be influenced by many factors that don't directly affect Chromocell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromocell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromocell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromocell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.